Eli Lilly and NVIDIA have recently announced a collaboration to build a new AI supercomputer dedicated to pharmaceutical research. The supercomputer will enable Eli Lilly to accelerate molecular simulations, analyze protein structures, and train large scale AI models for drug discovery and clinical research. By merging advanced AI with deep biological insight, the partnership is set to reshape the global drug discovery space, according to GlobalData, a leading data and analytics company.
According to GlobalData, the global market for specialized AI applications is forecast to reach $512 billion by 2030, driven largely by adoption in healthcare and life sciences. This partnership positions both companies at the forefront of digital transformation.
George El-Helou, Strategic Intelligence Analyst at GlobalData, comments: “AI is reshaping how we approach healthcare innovation. By combining NVIDIA’s computing power with Eli Lilly’s scientific expertise, this partnership establishes a new gold standard for precision medicine.”
Eli Lilly will be the first company to operate a full-scale “AI factory” for life sciences, powered by NVIDIA’s DGX SuperPod systems, one of the world’s most advanced AI computing platforms. It plans to use the “AI factory” to reduce the time required to identify and test promising compounds. The company will integrate the platform across its global operations to advance drug modelling, predictive toxicology, and molecular design. This initiative also includes AI training and secure data sharing programs to streamline collaboration with biotech partners and academic institutions.
Gaffar Aga, Strategic Intelligence Analyst at GlobalData, comments: “Eli Lilly is moving from using AI as an analytical tool, to treating it as a scientific co-pilot. With this new infrastructure, researchers can generate and test hypotheses at a more rapid pace, significantly reducing R&D costs and time-to-market.”
NVIDIA’s BioNeMo platform will also allow external partners to access pre-trained AI models, promoting innovation across the industry, while preserving data privacy. Both companies have emphasized a privacy first approach, ensuring that proprietary data remains secure throughout research collaborations.
Aga and El-Helou conclude: “This alliance represents the convergence of two innovation leaders and marks a pivotal step towards a future where AI-driven supercomputing transforms the way new treatments are delivered on the global pharmaceutical market.”
